New drug combo shows promise for advanced kidney cancer

NCT ID NCT01684397

Ongoing Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study tested two drugs, pazopanib and bevacizumab, given in turns to people with advanced kidney cancer that had spread. The goal was to find the best dose and see if the combination could control tumor growth. 51 patients took part, and the study focused on safety and how long the cancer stayed stable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Karamanos Cancer Institute

Detroit, Michigan, 482018, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
The University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA STAGE IV RENAL CELL CANCER STAGE IV RENAL CELL CANCER